358 related articles for article (PubMed ID: 32741482)
1. The Role of Dopamine Agonists in Pituitary Adenomas.
Giraldi EA; Ioachimescu AG
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):453-474. PubMed ID: 32741482
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of pituitary adenomas].
Mezosi E; Nemes O
Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study.
Colao A; Zgliczyński W; Komorowski J; Kos-Kudła B; Tabarin A; Kerlan V; Minuto FM; Scaroni C; Bolanowski M
Endokrynol Pol; 2019; 70(4):305-312. PubMed ID: 31274183
[TBL] [Abstract][Full Text] [Related]
4. Cabergoline in acromegaly.
Kuhn E; Chanson P
Pituitary; 2017 Feb; 20(1):121-128. PubMed ID: 28025719
[TBL] [Abstract][Full Text] [Related]
5. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
6. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
Yamaguchi H; Shimatsu A; Okayama A; Sato T
Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069
[TBL] [Abstract][Full Text] [Related]
8. Medical approach to pituitary tumors.
Neggers SJ; van der Lely AJ
Handb Clin Neurol; 2014; 124():303-16. PubMed ID: 25248595
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
10. Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy.
Vilar L; Czepielewsk MA; Naves LA; Rollin GA; Casulari LA; Coelho CE
Endocr Pract; 2007; 13(4):396-402. PubMed ID: 17669717
[TBL] [Abstract][Full Text] [Related]
11. Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives.
Cuny T; Barlier A; Feelders R; Weryha G; Hofland LJ; Ferone D; Gatto F
Ann Endocrinol (Paris); 2015 Feb; 76(1):43-58. PubMed ID: 25556152
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications.
Lin S; Zhang A; Zhang X; Wu ZB
Neuroendocrinology; 2020; 110(6):477-488. PubMed ID: 31597135
[TBL] [Abstract][Full Text] [Related]
13. Multimodality treatment of pituitary adenomas.
Oyesiku NM
Clin Neurosurg; 2005; 52():234-42. PubMed ID: 16626076
[No Abstract] [Full Text] [Related]
14. IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas.
Akirov A; Greenman Y; Glaser B; S'chigol I; Mansiterski Y; Eizenberg Y; Shraga-Slutzky I; Shimon I
Pituitary; 2018 Aug; 21(4):406-413. PubMed ID: 29728863
[TBL] [Abstract][Full Text] [Related]
15. Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.
Pivonello C; Patalano R; Negri M; Pirchio R; Colao A; Pivonello R; Auriemma RS
Front Endocrinol (Lausanne); 2021; 12():791633. PubMed ID: 35095761
[TBL] [Abstract][Full Text] [Related]
16. Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma.
Miyoshi T; Otsuka F; Takeda M; Inagaki K; Suzuki J; Ogura T; Date I; Hashimoto K; Makino H
J Endocrinol Invest; 2004 Dec; 27(11):1055-9. PubMed ID: 15754738
[TBL] [Abstract][Full Text] [Related]
17. The role of primary pharmacological therapy in acromegaly.
Espinosa de los Monteros AL; Carrasco CA; Albarrán AA; Gadelha M; Abreu A; Mercado M
Pituitary; 2014 Jan; 17 Suppl 1(Suppl 1):S4-10. PubMed ID: 24166706
[TBL] [Abstract][Full Text] [Related]
18. Current pharmacotherapy for acromegaly: a review.
Biermasz NR; Romijn JA; Pereira AM; Roelfsema F
Expert Opin Pharmacother; 2005 Nov; 6(14):2393-405. PubMed ID: 16259571
[TBL] [Abstract][Full Text] [Related]
19. Evidence for dopamine agonists in the treatment of acromegaly.
Jaquet P
J Endocrinol; 1997 Oct; 155 Suppl 1():S59-60. PubMed ID: 9389998
[No Abstract] [Full Text] [Related]
20. Treatment of pituitary tumors: dopamine agonists.
Iván G; Szigeti-Csúcs N; Oláh M; Nagy GM; Góth MI
Endocrine; 2005 Oct; 28(1):101-10. PubMed ID: 16311416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
